ClinicalTrials.gg
RecruitingNCT02065921Updated Nov 2, 2026

Swiss Chronic Obstructive Pulmonary Disease (COPD) Management Cohort

An observational study in Chronic Obstructive Pulmonary Disease and COPD Exacerbation, sponsored by Prof. Dr. Jörg Leuppi. Recruiting at 1 site in Switzerland. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Prof. Dr. Jörg Leuppi · Observational

How we know

Updated Nov 2, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
265
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland — 15 open to participants now, 20 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Switzerland.

Planned enrollment
9th of 22
265 · median 128
Started
2006
with 3 others
Observational
22 of 99
5 open now
Primary completion
2026-12
later than 6 of 19 live
Registered
32nd of 99
by date

Among the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland, this one is the 9th largest by planned enrollment of the 22 observational ones that give a count, is one of 4 that started in 2006, is one of 22 observational ones, reaches primary completion later than 6 of the 19 other live ones, and was the 32nd registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

15 of the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland, or all of them as a file.
02

Study summary

  1. Background Chronic Obstructive Pulmonary Disease (COPD) is an inflammatory disease of the lungs, which is most commonly caused by smoking. It is characterized as not fully reversible airflow limitation, chronic cough and dyspnoea. Being the fourth leading cause of death worldwide, COPD is an important public health challenge and can be prevented and treated. It is estimated that at least 400,000 individuals in Switzerland are affected by COPD. This number may increase in the coming years due to increasing nicotine consumption.

    In response to the rising trend, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has established new guidelines on the global strategy for diagnosis, management and prevention of COPD. Systematic diagnosis and stratification are crucial for effective treatment measures.

    As COPD is an irreversible and progressive disease, its treatment aims an early detection and better management, which leads preventing progression. Disease management programs have shown that only patients who understand their exacerbation symptoms can benefit. Moreover, it is a major goal to improve health-related quality of life by reducing symptoms and decelerating disease progression.

    Spirometry is the golden standard for the diagnosis of COPD, to assess the severity of the obstruction, and as a guide for optimal therapeutic measures.

  2. Aim of the study The objective of this project is to establish a COPD cohort database to allow high quality research on diagnosis, treatment, complication and progression of COPD on long-term course.

    Spirometry should be used consistently for the diagnosis and the monitoring of the development of the disease. Using collected information such as spirometric data, disease progression's data and therapeutic measures should help improve the management and self-management of the patients.

  3. Methods 3.1 Study design We are conducting a prospective cohort study, based on COPD patients from northern and western Switzerland, who are managed under primary care setting. Patients with mild to very severe COPD (GLOD stages I-IV) are enrolled in the study.

    Currently, 67 General practitioners (GPs) are participating in our Study. Each GP recruits 1-20 patients with presumed mild to very severe COPD according to criteria of the Global Initiative for Chronic Obstructive Lung disease [GOLD].

    Patients' follow-up-visits occurs at 6-month intervals; their history, symptoms and examination status is recorded. Data is entered into an online database either by the physicians or by study team after receiving the collected data questionnaires by facsimile.

    Data collection includes demographic data, physical examination, spirometric parameters, medical treatment and exacerbation history besides death.

    A spirometer (EasyOne™, ndd Medizintechnik AG, Zürich, Switzerland) is used to assess lung function. All participating physicians were instructed on the usage of the spirometer and on how to complete spirometry according to the guidelines. For the assessment of the severity of COPD, we use the spirometric data provided by the GPs. The COPD severity is interpreted according to criteria of the GOLD committee.

    3.2 Patient population Patients with newly diagnosed or existing COPD, who are managed in primary-care practices.

    3.3 Inclusion criteria

    • Tiffenau (FEV17FVC) \< 70 without reversibility (Increase in FEV1 after inhalation of a bronchodilator \<200 ml and \<12%).
    • Age: > 40 years
    • Both genders
    • Smokers or ex-smokers of at least 20 pack years.
    • Informed consent.

    3.4 Archiving and Data Retention All study-related records such as medical records, informed consent documents, information regarding participants who discontinued, and other pertinent data will be maintained and therefore retained as long as required by the applicable Swiss regulatory requirements (10 Years).

    3.5 Data security The complete data of the study will be entered anonymously into a database. The data is password-protected and can only be accessed by investigators and study members.

  4. Publication and authorship 4.1 Publication policy

Authorship credit is based on:

  1. Substantial contribution to conception and design, acquisition of data, or analysis and interpretation of data.
  2. Drafting the article or revising it critically for important intellectual content.
  3. Final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • COPD Exacerbation

Keywords

  • COPD cohort
  • COPD management
  • exacerbation
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with newly diagnosed or existing COPD, who are managed in primary-care practices.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Tiffenau (FEV17FVC) \< 70 without reversibility (Increase in after inhalation of a bronchodilator \<200 ml and \<12%).
  • Age: > 40 years
  • Both genders
  • Smokers or ex-smokers of at least 20 pack years.
  • .

Exclusion criteria

Exclusion Criteria:

  • \< 40 Years
  • Tiffenau (FEV17FVC) > 70
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
265 participants (estimated)
Patient registry
No

Groups and cohorts

  • COPD patients

    establishing COPD cohort database to allow high quality research on diagnosis, treatment, complication and progression of COPD on long-term course.

06

What researchers measure

Primary outcomes

  1. Number of exacerbation

    no. of exacerbation and time to exacerbation over a time period of 2 years.

    Time frame: 24 months

Secondary outcomes

  1. Disease progression

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Cantonal Hospital Baselland, Internal medicine University clinic
    Liestal, Basel-Landschaft 4410, Switzerland
    Recruiting
    • Jörg D Leuppi, MD, PhD, Prof. · Contactjoerg.leuppi@ksbl.ch · 0041 61 925 21 80
    • Jörg D Leuppi, MD, PhD, Prof. · Principal investigator
08

References and documents

Publications

  • Jochmann A, Scherr A, Jochmann DC, Miedinger D, Torok SS, Chhajed PN, Tamm M, Leuppi JD. Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort. Swiss Med Wkly. 2012 Apr 5;142:w13567. doi: 10.4414/smw.2012.13567. eCollection 2012. PubMed 22481636 ↗
  • Jochmann A, Neubauer F, Miedinger D, Schafroth S, Tamm M, Leuppi JD. General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med Wkly. 2010 Aug 9;140:10.4414/smw.2010.13053. doi: 10.4414/smw.2010.13053. eCollection 2010. PubMed 20407960 ↗
  • Urwyler P, Abu Hussein N, Bridevaux PO, Chhajed PN, Geiser T, Grendelmeier P, Joos Zellweger L, Kohler M, Maier S, Miedinger D, Tamm M, Thurnheer R, Dieterle T, Leuppi JD. Predictive factors for exacerbation and re-exacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohort. Multidiscip Respir Med. 2019 Feb 5;14:7. doi: 10.1186/s40248-019-0168-5. eCollection 2019. PubMed 30774953 ↗
09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Sep 2006, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Sep 2025 → Dec 2026 and completion Sep 2025 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2014
First posted
Feb 19, 2014
Start
Sep 2006
Primary completionEst.
Dec 2026was Sep 2025
CompletionEst.
Dec 2026was Sep 2025
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Cantonal Hospital Baselland, Internal medicine University clinic · Liestal, Switzerland
Show 1 removed
  • Cantonal Hospital Baselland, Internal medicine University clinic · Liestal, Switzerland
Nov 2, 2026
Primary completion
Sep 2025→Dec 2026
Nov 2, 2026
Study completion
Sep 2025→Dec 2026
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    1 site added, 1 site removed
    Show site
    • Cantonal Hospital Baselland, Internal medicine University clinic · Liestal, Switzerland
    Show 1 removed
    • Cantonal Hospital Baselland, Internal medicine University clinic · Liestal, Switzerland
    Primary completion Sep 2025→Dec 2026
    Study completion Sep 2025→Dec 2026
    + 4 other changes: identifiers, verification date, responsible party and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02065921
Lead sponsor
Prof. Dr. Jörg Leuppi
Responsible party
Prof. Dr. Jörg Leuppi (Chief of University medical Department Cantonal Hospital Baselland, Cantonal Hospital, Baselland) — Sponsor-investigator
First posted
Feb 19, 2014
Start date
Sep 2006
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 2, 2026

Study contacts

Jörg D Leuppi, MD, PhD,Prof.
Contact
joerg.leuppi@ksbl.ch
061 925 2180

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion